Sign up to access all our data and the evidence and analysis underlying our overall scores. Once you've created an account, we'll get in touch with further details:
Sign Up
| Overall Assessment |
Comment |
Score |
| None |
No evidence found
|
0
|
| Overall Assessment |
Comment |
Score |
| None |
TTY Biopharm Co Ltd discloses a detailed sustainability governance structure—“永續發展委員會隸屬於董事會” with three functional centers for sustainable development, integrity management and risk management—and notes that “The Board of Directors is the highest body to guide and supervise climate change policies” and that the “Risk Management Center is the dedicated unit for climate change management,” but we found no evidence of any governance process for lobbying or policy advocacy. The disclosures do not describe any mechanism to align direct or indirect lobbying with climate objectives, no “process for how these activities are monitored or managed” and no specific individual or formal body tasked with overseeing lobbying alignment. Although the company “regularly participates the Chinese Association for Pharmaceutical Agents (CAPA) & Taipei Pharmaceutical Agents and Distribution Association (TPADA) meetings,” these activities are presented in the context of sales and licensing strategies rather than climate-policy engagement. Overall, the company’s reporting centers on internal sustainability, integrity and climate risk management without addressing any lobbying governance or oversight.
|
0
|